Deferitazole

Drug Profile

Deferitazole

Alternative Names: Deferitazole magnesium; FBS-0701; SHP602; SPD-602; SSP-004184; SSP-004184AQ; SSP-004184SS

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator FerroKin BioSciences
  • Class Heterocyclic acids; Small molecules; Thiazoles
  • Mechanism of Action Iron chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Iron overload
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Iron overload

Most Recent Events

  • 18 Mar 2014 Suspended - Phase-I for Iron overload in Australia (PO)
  • 18 Mar 2014 Suspended - Phase-II for Iron overload in USA, Canada, Italy, Lebanon, Thailand, Turkey and United Kingdom before March 2014 (PO)
  • 18 Mar 2014 Suspended - Phase-II for Iron overload (in children and adolescents) in USA, Canada and Italy before March 2014 (Oral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top